• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Pacific Biosciences of California Inc. (Amendment)

    2/12/24 5:12:09 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PACB alert in real time by email
    SC 13G/A 1 ef20021452_sc13ga.htm SC 13G/A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

    Pacific Biosciences of California, Inc.

    (Name of Issuer)

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    69404D108

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No.

    1
    NAMES OF REPORTING PERSONS
     
     
    Nikko Asset Management Americas, Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     

     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    USA
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    12,270,457
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    13,200,375
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    13,200,375
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    4.93%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IA
     
     
     
     


    Item 1.

     
    (a)
    Name of Issuer
     
    Pacific Biosciences of California, Inc.
         
     
    (b)
    Address of Issuer’s Principal Executive Offices
     
    1305 O’Brien Drive, Menlo Park, CA 94025

    Item 2.

     
    (a)
    Name of Person Filing
     
    Nikko Asset Management Americas, Inc.
         
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
    605 Third Avenue, 38th Floor, New York, NY 10158
         
     
    (c)
    Citizenship
     
    USA
         
     
    (d)
    Title of Class of Securities
     
    Common Stock, par value $0.001 per share
         
     
    (e)
    CUSIP Number
     
    69404D108

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    ☐
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
     
    (b)
    ☐
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
     
    (c)
    ☐
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
     
    (d)
    ☐
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
           
     
    (e)
    ☒
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
     
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
     
    (g)
    ☐
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);


     
    (h)
    ☐
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
     
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
     
    (j)
    ☐
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
           
     
    (k)
    ☐
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


    Item 4.
    Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     
    (a)
    Amount beneficially owned:
     
    13,200,375
           
     
    (b)
    Percent of class:
     
    4.93%
           
     
    (c)
    Number of shares as to which the person has:
           
       
    (i)
    Sole power to vote or to direct the vote:
     
    0
           
       
    (ii)
    Shared power to vote or to direct the vote:
     
    12,270,457
           
       
    (iii)
    Sole power to dispose or to direct the disposition of:
     
    0
           
       
    (iv)
    Shared power to dispose or to direct the disposition of:
     
    13,200,375

    Item 5.
    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    See Exhibit A.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    See Exhibit A.

    Item 8.
    Identification and Classification of Members of the Group

    Not Applicable.

    Item 9.
    Notice of Dissolution of Group

    Not Applicable.


    Item 10.
    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 12, 2024
    By:
    /s/ Gary L. Beckham
       
    Name: Gary L. Beckham
       
    Title: Chief Compliance Officer

    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)


    Exhibit A

    Pursuant to the instructions in Items 6 and 7 of Schedule 13G, the security being reported on by Nikko Asset Management Americas, Inc., as subsidiary to the parent holding companies listed below, are owned, or may be deemed to be beneficially owned, by its parent holding companies.


    1)
    Sumitomo Mitsui Trust Holdings Inc.

    o
    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

    o
    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).


    2)
    Nikko Asset Management Co., Ltd.

    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

    o
    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).



    Get the next $PACB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PACB

    DatePrice TargetRatingAnalyst
    3/6/2026$1.50Equal Weight → Underweight
    Barclays
    11/11/2024Buy → Neutral
    UBS
    6/3/2024$4.00Buy
    Jefferies
    4/22/2024Overweight → Neutral
    JP Morgan
    4/18/2024$7.00 → $2.50Buy → Neutral
    Goldman
    12/14/2023$11.00Overweight
    Stephens
    12/14/2023Neutral
    Guggenheim
    12/13/2023Peer Perform
    Wolfe Research
    More analyst ratings

    $PACB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Pacific Biosciences downgraded by Barclays with a new price target

    Barclays downgraded Pacific Biosciences from Equal Weight to Underweight and set a new price target of $1.50

    3/6/26 8:26:02 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Pacific Biosciences downgraded by UBS

    UBS downgraded Pacific Biosciences from Buy to Neutral

    11/11/24 9:44:33 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Jefferies resumed coverage on Pacific Biosciences with a new price target

    Jefferies resumed coverage of Pacific Biosciences with a rating of Buy and set a new price target of $4.00

    6/3/24 8:16:36 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gibson Christopher was granted 53,913 shares (SEC Form 4)

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    3/5/26 8:43:24 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 3 filed by new insider Gibson Christopher

    3 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    3/5/26 8:39:25 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Henry Christian O sold $18,920 worth of shares (12,497 units at $1.51), decreasing direct ownership by 0.35% to 3,581,813 units (SEC Form 4)

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    3/4/26 5:55:22 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research

    MENLO PARK, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, today announced a collaboration with DNAstack to power the world's first global federated dataset of HiFi whole genome sequencing data. Through the HiFi Solves Global Consortium, the collaboration enables secure international research — allowing genomic insights to travel across borders while sensitive data remains under institutional control. Participating institutions connect HiFi whole genome sequencing data and associated metadata within a highly secure federated environment. Hosted by DNAstack and accessible at https://hifisolves.org, the platfor

    2/24/26 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio to Participate in the TD Cowen 46th Annual Health Care Conference

    MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on Monday, March 2, 2026, at 2:30 PM ET in Boston, MA. A live webcast of the event can be accessed at the company's investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event. About PacBio PacBio (NASDAQ:PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and cli

    2/18/26 4:05:00 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    SEC Filings

    View All

    $PACB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure

    8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

    3/6/26 4:06:02 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Pacific Biosciences of California Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Filer)

    3/5/26 8:34:48 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 144 filed by Pacific Biosciences of California Inc.

    144 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    3/3/26 4:20:56 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Meline David W bought $176,160 worth of shares (40,000 units at $4.40) (SEC Form 4)

    4 - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Issuer)

    3/6/24 5:36:07 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/26/24 8:27:01 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Pacific Biosciences of California Inc.

    SC 13G - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/14/24 5:52:54 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Pacific Biosciences of California Inc.

    SC 13G/A - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (0001299130) (Subject)

    11/14/24 5:48:11 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Leadership Updates

    Live Leadership Updates

    View All

    PacBio Announces the Appointment of Chris Gibson to the Board of Directors

    MENLO PARK, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio's Board of Directors. Dr. Gibson is the co-founder and Chairman of the Board of Directors of Recursion (NASDAQ:RXRX), a clinical-stage biotechnology company that has built one of the industry's most advanced AI-driven drug discovery platforms. Under his leadership, Recursion integrated large-scale biological data generation with machine learning to industrialize the discovery process, building a vertically integrated technology stack spanning automation, high-dimensional b

    3/5/26 8:30:00 AM ET
    $PACB
    $RXRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PacBio Expands Distribution in China, Gaining Access to New Clinical Lab Networks via Haorui Gene

    MENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as an official distributor in China. The distribution arrangement is designed to expand access to PacBio's HiFi long-read sequencing technology in clinical and research settings, with a focus on transfusion medicine and hematology, areas where precision and completeness of genomic data are critical to patient outcomes. Founded in 2020, Haorui Gene has quickly become a key player in blood typing genomics, deploying seven Sequel II and three R

    5/22/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Jim Gibson to join PacBio as Chief Financial Officer

    MENLO PARK, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced Jim Gibson will join and be appointed as the company's new Chief Financial Officer, effective as of his start date, which is expected to be March 31, 2025. With over three decades of financial leadership experience at some of Silicon Valley's most iconic and innovative companies, Mr. Gibson brings a deep track record of operational excellence, strategic financing, and scaling global organizations. Mr. Gibson joins PacBio from Sequoia, a strategic compensation and benefits solutions provider, where he served as CFO across

    3/27/25 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PACB
    Financials

    Live finance-specific insights

    View All

    PacBio Announces Fourth Quarter and Full Year 2025 Financial Results

    MENLO PARK, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter and fiscal year ended December 31, 2025. Fourth quarter and full year results:  Q4 2025Q4 2024FY 2025FY 2024Revenue (in millions)$44.6$39.2$160.0$154.0Consumable revenue (in millions)$21.6$18.8$82.0$70.3Instrument revenue (in millions)$17.3$15.3$53.8$65.8Service and other revenue (in millions)$5.7$5.1$24.2$17.9RevioTM system placements21236197VegaTM system placements4271407Annualized Revio pull-through per system~$242,000~$240,000~$233,000~$252,000Ending cash, cash equivalents, and investments(in millions)$279.5$389.9   Gross margin, operating expenses, net inco

    2/12/26 4:05:00 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026

    MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, at 5:00 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, February 12, 2026, at 5:00 pm ET (2:00 pm PT) Listen live via internet or replay: https://investor.pacificbiosciences.com/ Toll-free: 1-888-349-0136 International: 1-412-317-0459 About PacBio PacBio (NASDAQ:PACB) is a premier life science technology company that designs, develops, and manufactures advan

    1/27/26 4:05:00 PM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PacBio Announces Preliminary Fourth Quarter and Full Year 2025 Revenue

    MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2025 and full year 2025 of $44.6 million and $160.0 million representing year-over-year growth of 14% and 4%, respectively. "We finished the year with strong momentum driven by increased Revio and Vega sales as well as record consumables revenue, reflecting meaningful traction across a range of clinical sequencing applications," said Christian Henry, President and CEO of PacBio. "In 2025, we also significantly reduced our cash burn and strengthened our financial profile. Look

    1/12/26 9:05:00 AM ET
    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials